Global Skin Cancer Market - 2025 -2033

October 2025 | 180 pages | ID: G2FF46674C4BEN
DataM Intelligence

Abstracts

Skin Cancer Market Size & Industry Outlook

The global skin cancer market size reached US$ 10.61 Billion in 2024 from US$ 9.92 Billion in 2023 and is expected to reach US$ 20.48 Billion by 2033, growing at a CAGR of 7.6% during the forecast period 2025-2033.

The market is evolving rapidly, driven by rising global incidence of melanoma and non-melanoma cases due to increased UV exposure, aging populations, and improved screening awareness. Immunotherapies like PD-1 inhibitors, BRAF/MEK targeted regimens, and hedgehog pathway inhibitors are transforming standards of care, while novel modalities such as mRNA vaccines and TIL therapies are progressing through clinical trials. Alongside these advances, the growing role of teledermatology and digital health tools highlights a shift toward earlier intervention and decentralized care delivery.

Key Market Trends & Insights

• Key trends shaping the skin cancer market include the integration of AI and digital health tools, with solutions like AI-powered dermatoscopes and teledermatology platforms gaining adoption for early detection and remote triage. In therapeutics, immuno-oncology continues to dominate, with PD-1 inhibitors expanding into earlier-stage melanoma and combination regimens showing durable survival benefits.
• Targeted therapies like BRAF/MEK inhibitors and hedgehog pathway drugs remain critical in biomarker-driven care, while emerging modalities such as mRNA vaccines and tumor-infiltrating lymphocyte (TIL) therapies are advancing through late-stage clinical trials.
• There is also a notable push toward adjuvant and neoadjuvant therapy adoption in high-risk patients, reflecting a shift to earlier intervention strategies. Finally, the market is witnessing strong growth, supported by patient demand for less invasive, cost-effective treatment pathways.
• North America dominates the skin cancer market with the largest revenue share of 44.52% in 2024.
• The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 7.1% over the forecast period.
• Based on cancer type, the non-melanoma segment led the market with the largest revenue share of 54.95% in 2024.
• The major market players in the skin cancer market are Merck & Co., Inc., Amgen, Inc., Pfizer Inc., Genentech USA, Inc., Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries, Inc., Immunocore Ltd., IOVANCE Biotherapeutics, Inc., and Incyte among others

Market Size & Forecast

• 2024 Market Size: US$ 10.61 Billion
• 2033 Projected Market Size: US$ 20.48 Billion
• CAGR (2025–2033): 7.6%
• North America: Largest market in 2024
• Asia Pacific: Fastest-growing market

Market Dynamics

Drivers:

The rising incidence of skin cancer cases is significantly driving the skin cancer market growth

The global burden of skin cancer is rising alarmingly new cases surged, for instance, according to the Skin Cancer Foundation, in the U.S., more than 9,500 people are diagnosed with skin cancer every day. More than two people die of the disease every hour. Actinic keratosis is the most common precancer, it affects more than 58 million Americans. This surge in cases is fueling unprecedented demand for market.

This epidemiology rise is fueling adoption of checkpoint inhibitors such as pembrolizumab and nivolumab, which are now used not only in advanced melanoma but also in adjuvant and neoadjuvant settings, broadening their market share. Similarly, BRAF/MEK targeted therapies like dabrafenib plus trametinib are in strong demand for biomarker-positive melanoma patients, while hedgehog pathway inhibitors such as vismodegib and sonidegib address advanced basal cell carcinoma cases that are inoperable.

Even topical agents like imiquimod and 5-fluorouracil are seeing heightened usage in non-melanoma cancers due to increased diagnoses at early stage. Moreover, clinical innovation pipelines, such as mRNA-based melanoma vaccines, tumor-infiltrating lymphocyte (TIL) therapies, and intralesional oncolytic viruses are positioned to capture expanding patient segments as incidence continues to rise. Thus, the growing prevalence of skin cancer is not only creating a larger treated population but also driving the rapid uptake and diversification of therapeutic products across oncology markets.

Restraints:

The high cost of advanced therapies is hampering the growth of the skin cancer market

The high cost of advanced therapies remains a major restraint in the skin cancer market, significantly limiting access and adoption despite their proven clinical benefits. Modern treatments such as immune checkpoint inhibitors (pembrolizumab, nivolumab) and targeted agents (BRAF/MEK inhibitors for melanoma or hedgehog inhibitors like vismodegib for basal cell carcinoma) can cost patients and healthcare systems, placing immense financial pressure on payers and families.

For instance, according to the Skin Cancer Foundation, the annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion, about $4.8 billion for nonmelanoma skin cancers and $3.3 billion for melanoma. These high costs not only hinder equitable patient access but also slow down market penetration in emerging economies, where incidence is rising but advanced care infrastructure and funding remain inadequate. As a result, while innovation is expanding therapeutic options, the pricing barrier acts as a drag on overall market growth, reinforcing the need for sustainable pricing models, broader reimbursement frameworks, and the development of cost-effective alternatives.

Skin Cancer Market Segment Analysis

The global skin cancer market is segmented based on cancer type, treatment, end-user, and region.

Cancer Type:

The non-melanoma segment is dominating the skin cancer market with a 54.95% share in 2024

The non-melanoma skin cancer segment, comprising primarily basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), dominates the skin cancer market by sheer incidence and treatment volume, even though melanoma attracts more R&D and premium therapeutics. Globally, NMSCs account for nearly 90% of all skin cancer diagnoses, with the American Cancer Society estimating 3.6 million new BCC cases and 1.8 million new cSCC cases annually in the U.S. alone. This overwhelming caseload drives consistent demand for market.

For advanced cases, systemic therapies like hedgehog pathway inhibitors (vismodegib, sonidegib) have opened a new therapeutic avenue, addressing previously untreatable BCCs, though high costs limit broad use. The NMSC segment also benefits from field cancerization management, where large areas of sun-damaged skin are treated to prevent progression to invasive disease, further fueling use of topicals and PDT.

Basal cell carcinoma is far more common than squamous cell carcinoma. About 80% of non-melanoma skin cancers are basal cell carcinoma. Thus, it is the most common malignancy in the United States, with substantial associated morbidity and cost and relatively small but significant mortality. Treatment for non-melanoma skin cancer is usually successful, as unlike the other types of cancer, there's a significantly lower risk of cancer spreading to other parts of the body. Treatment for non-melanoma skin cancer is successful in approximately 90% of cases. Hence, the increasing rates of non-melanoma skin cancer and its success rates after treatment will drive the market's growth in the forecast period.

End-User:

The hospitals segment is dominating the skin cancer market with a 49.75% share in 2024

The hospitals segment is dominating the global skin cancer market due to its central role in diagnosis, treatment, and post-treatment care, supported by advanced infrastructure and multidisciplinary expertise. Hospitals handle the bulk of skin biopsies and histopathology tests, which are critical for confirming melanoma and non-melanoma cases, and they are typically well-equipped to improve diagnostic accuracy. In terms of therapeutics, hospitals dominate because they are the only settings capable of administering advanced immunotherapies like pembrolizumab (Keytruda) and nivolumab (Opdivo), or targeted therapies such as dabrafenib plus trametinib for BRAF-mutant melanoma.

Hospitals also manage patients on hedgehog inhibitors (vismodegib, sonidegib) for advanced basal cell carcinoma, which require close monitoring due to safety concerns. In countries like the US, hospitals lead large-scale screening programs and awareness campaigns, which drive early detection and patient referrals. Additionally, hospitals are the hub for clinical trials of cutting-edge modalities like mRNA melanoma vaccines, TIL therapies, and oncolytic viruses, further strengthening their market dominance. Given their concentration of specialized oncologists, dermatologists, pathologists, and advanced technologies, hospitals not only dominate patient care pathways but also capture the largest revenue share in the skin cancer market, making them the cornerstone of both diagnostic and therapeutic growth.

Market Geographical Analysis

North America is expected to dominate the global skin cancer market with a 44.52% in 2024

North America dominates the global skin cancer market due to its high disease prevalence, advanced healthcare infrastructure, and strong adoption of innovative diagnostics and therapeutics. The US dominates the market in the North America region with an 86.12% share in 2024, and it records some of the highest incidence rates globally, with the Skin Cancer Foundation projecting about 212,200 new melanoma cases in 2025, alongside millions of non-melanoma cases annually, making skin cancer the most common cancer in the country. This enormous patient pool drives steady demand for the market, with North America accounting for the largest installed base of digital dermatoscopes, reflectance confocal microscopy (RCM), and optical coherence tomography (OCT) systems.

North America has been the earliest and fastest adopter of immuno-oncology drugs, with checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) widely prescribed for melanoma and covered under major reimbursement frameworks. Similarly, targeted therapies like dabrafenib/trametinib for BRAF-mutant melanoma and hedgehog inhibitors (vismodegib, sonidegib) for advanced basal cell carcinoma are routinely available, ensuring premium revenue streams for pharmaceutical companies.

Favorable reimbursement, well-structured awareness programs like Skin Cancer Awareness Month, and a high concentration of dermatology specialists create an environment conducive to both diagnostic and therapeutic growth. Collectively, these factors position North America as the largest and most lucrative region in the global skin cancer market, with sustained leadership driven by its combination of high incidence, innovation, and healthcare accessibility.

The Asia Pacific region is the fastest-growing region in the global skin cancer market, with a CAGR of 7.1% in 2024

The Asia Pacific (APAC) region is emerging as the fastest-growing segment of the global skin cancer market, driven by rising incidence, improving healthcare infrastructure, and rapid adoption of innovative therapies and diagnostics. While historically considered a low-incidence region, changing lifestyles, urbanization, and increasing UV exposure are contributing to a sharp rise in both melanoma and non-melanoma cases. For instance, China has reported increasing non-melanoma skin cancer mortality over the last three decades, signaling a significant epidemiological shift.

Growing awareness campaigns across India, Japan, and South Korea are further expanding screening uptake and encouraging preventive care. The region has rapidly adopted immuno-oncology drugs like pembrolizumab and nivolumab, alongside targeted therapies for biomarker-positive melanoma, supported by government-led efforts to expand oncology drug reimbursement. Local companies are also investing in biosimilars and cost-effective generics, making advanced treatments more accessible to a broader population.

Skin Cancer Market Top Companies

Top companies in the skin cancer market include Merck & Co., Inc., Amgen, Inc., Pfizer Inc., Genentech USA, Inc., Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries, Inc., Immunocore Ltd., IOVANCE Biotherapeutics, Inc. and Incyte, among others.

Recent Developments

• In May 2025, Intermountain Health has launched a new program to provide tumor-infiltrating lymphocyte (TIL) therapy to treat patients with a type of skin cancer called unresectable or metastatic melanoma that cannot be removed surgically or has spread to other parts of the body. As part of the treatment process, doctors use AMTAGVI, the first and only FDA-approved prescription medication for the treatment of advanced melanoma that has not responded to standard therapies. AMTAGVI activates the patient's own immune system to target and destroy cancer cells and represents a different approach compared to other immunotherapies. Instead of broadly stimulating the immune system, it harnesses a patient's own tumor-specific T cells to directly target and destroy cancer cells.

The global skin cancer market report delivers a detailed analysis with 62 key tables, more than 55 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

3.1. Key Trends and Future Projections

4. SNIPPET BY CANCER TYPE

4.1. Snippet by Treatment
4.2. Snippet by End-User
4.3. Snippet by Region

5. DYNAMICS

5.1. Impacting Factors
  5.1.1. Drivers
    5.1.1.1. Rising Incidence of Skin Cancer Cases
    5.1.1.2. Advancements in Immuno-Oncology and Targeted Therapies
  5.1.2. Restraints
    5.1.2.1. High Cost of Advanced Therapies
    5.1.2.2. Safety and Side-Effect Burden
  5.1.3. Opportunity
    5.1.3.1. Emergence of Novel Modalities, Vaccines, TILs, and Oncolytic Viruses
    5.1.3.2. Teledermatology and Remote Care Models
  5.1.4. Impact Analysis

6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

6.1. Market Leaders and Pioneers
  6.1.1. Emerging Pioneers and Prominent Players
  6.1.2. Established Leaders with the Largest Marketing Brand
  6.1.3. Market Leaders with Established Products
6.2. Latest Developments and Breakthroughs
6.3. Regulatory and Reimbursement Landscape
  6.3.1. North America
  6.3.2. Europe
  6.3.3. Asia Pacific
  6.3.4. South America
  6.3.5. Middle East & Africa
6.4. Porter’s Five Forces Analysis
6.5. Patent Analysis
6.6. Unmet Needs and Gaps
6.7. Recommended Strategies for Market Entry and Expansion
6.8. Pricing Analysis and Price Dynamics

7. SKIN CANCER MARKET, BY CANCER TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Non-Melanoma*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  7.2.3. Basal Cell Carcinoma
  7.2.4. Squamous Cell Carcinoma.
  7.2.5. Merkel Cell Cancer
  7.2.6. Others
7.3. Melanoma

8. SKIN CANCER MARKET, BY TREATMENT

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  8.1.2. Market Attractiveness Index, By Treatment
8.2. Immunotherapy*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chemotherapy
8.4. Photodynamic Therapy
8.5. Targeted Therapy
8.6. Radiation Therapy
8.7. Others

9. SKIN CANCER MARKET, BY END-USER

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Dermatology Clinics
9.4. Academic and Research Institutes
9.5. Others

10. SKIN CANCER MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

11. INTRODUCTION

11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.1. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.6.1. U.S.
    11.2.6.2. Canada
    11.2.6.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.6.1. Germany
    11.3.6.2. UK
    11.3.6.3. France
    11.3.6.4. Spain
    11.3.6.5. Italy
    11.3.6.6. Rest of Europe
11.4. Asia-Pacific
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.6.1. China
    11.4.6.2. India
    11.4.6.3. Japan
    11.4.6.4. South Korea
    11.4.6.5. Rest of Asia-Pacific
11.5. South America
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.6.1. Brazil
    11.5.6.2. Argentina
    11.5.6.3. Rest of South America
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS

13.1. Market Share Analysis and Positioning Matrix
13.2. Strategic Partnerships, Mergers & Acquisitions
13.3. Key Developments in Product Portfolios and Innovations
13.4. Company Benchmarking

14. COMPANY PROFILES

14.1. Merck & Co., Inc.*
  14.1.1. Company Overview
  14.1.2. Product Portfolio
    14.1.2.1. Product Description
    14.1.2.2. Product Key Performance Indicators (KPIs)

15. FINANCIAL OVERVIEW

15.1. Company Revenue
  15.1.1. Geographical Revenue Shares
    15.1.1.1. Revenue Forecasts
  15.1.2. Key Developments
    15.1.2.1. Mergers & Acquisitions
    15.1.2.2. Key Product Development Activities
    15.1.2.3. Regulatory Approvals, etc.
  15.1.3. SWOT Analysis
15.2. Amgen, Inc.
15.3. Pfizer Inc.
15.4. Genentech USA, Inc.
15.5. Regeneron Pharmaceuticals, Inc.
15.6. Bristol-Myers Squibb Company
15.7. Sun Pharmaceutical Industries, Inc.
15.8. Immunocore Ltd.
15.9. IOVANCE Biotherapeutics, Inc.
15.10. Incyte
LIST NOT EXHAUSTIVE

1. ASSUMPTIONS AND RESEARCH METHODOLOGY

1. DATA COLLECTION METHODS

2. DATA TRIANGULATION

3. FORECASTING TECHNIQUES

4. DATA VERIFICATION AND VALIDATION

2. APPENDIX

1. ABOUT US AND SERVICES

2. CONTACT US

List Of Tables

LIST OF TABLES

Table 1 Global Skin Cancer Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Skin Cancer Market Value, By Treatment, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Skin Cancer Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Skin Cancer Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Skin Cancer Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Skin Cancer Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 7 Global Skin Cancer Market Value, By Treatment, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Skin Cancer Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 9 Global Skin Cancer Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Skin Cancer Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global Skin Cancer Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Skin Cancer Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Skin Cancer Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 14 North America Skin Cancer Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 15 North America Skin Cancer Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America Skin Cancer Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Skin Cancer Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 18 Europe Skin Cancer Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 19 Europe Skin Cancer Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe Skin Cancer Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Skin Cancer Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Skin Cancer Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Skin Cancer Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Skin Cancer Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Skin Cancer Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 26 South America Skin Cancer Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 27 South America Skin Cancer Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America Skin Cancer Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Skin Cancer Market Value, By Cancer Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Skin Cancer Market Value, By Treatment, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Skin Cancer Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Skin Cancer Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Merck & Co., Inc.: Overview
Table 34 Merck & Co., Inc.: Product Portfolio
Table 35 Merck & Co., Inc.: Key Developments
Table 36 Amgen, Inc.: Overview
Table 37 Amgen, Inc.: Product Portfolio
Table 38 Amgen, Inc.: Key Developments
Table 39 Pfizer Inc.: Overview
Table 40 Pfizer Inc.: Product Portfolio
Table 41 Pfizer Inc.: Key Developments
Table 42 Genentech USA, Inc.: Overview
Table 43 Genentech USA, Inc.: Product Portfolio
Table 44 Genentech USA, Inc.: Key Developments
Table 45 Regeneron Pharmaceuticals, Inc.: Overview
Table 46 Regeneron Pharmaceuticals, Inc.: Product Portfolio
Table 47 Regeneron Pharmaceuticals, Inc.: Key Developments
Table 48 Bristol-Myers Squibb Company: Overview
Table 49 Bristol-Myers Squibb Company: Product Portfolio
Table 50 Bristol-Myers Squibb Company: Key Developments
Table 51 Sun Pharmaceutical Industries, Inc.: Overview
Table 52 Sun Pharmaceutical Industries, Inc.: Product Portfolio
Table 53 Sun Pharmaceutical Industries, Inc.: Key Developments
Table 54 Immunocore Ltd.: Overview
Table 55 Immunocore Ltd.: Product Portfolio
Table 56 Immunocore Ltd.: Key Developments
Table 57 IOVANCE Biotherapeutics, Inc.: Overview
Table 58 IOVANCE Biotherapeutics, Inc.: Product Portfolio
Table 59 IOVANCE Biotherapeutics, Inc.: Key Developments
Table 60 Incyte: Overview
Table 61 Incyte: Product Portfolio
Table 62 Incyte: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Skin Cancer Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 3 Global Skin Cancer Market Share, By Treatment, 2024 & 2033 (%)
Figure 4 Global Skin Cancer Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global Skin Cancer Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Skin Cancer Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)
Figure 7 Non-Melanoma Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 8 Melanoma Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Skin Cancer Market Y-o-Y Growth, By Treatment, 2023-2033 (%)
Figure 10 Immunotherapy Treatment in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 11 Chemotherapy Treatment in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 12 Photodynamic Therapy Treatment in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 13 Targeted Therapy Treatment in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 14 Radiation Therapy Treatment in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Treatment in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Skin Cancer Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 17 Hospitals End-User in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 18 Dermatology Clinics End-User in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 19 Academic and Research Institutes End-User in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 20 Others End-User in Global Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Skin Cancer Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Skin Cancer Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 24 North America Skin Cancer Market Share, By Treatment, 2024 & 2033 (%)
Figure 25 North America Skin Cancer Market Share, By End-User, 2024 & 2033 (%)
Figure 26 North America Skin Cancer Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Skin Cancer Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 29 Europe Skin Cancer Market Share, By Treatment, 2024 & 2033 (%)
Figure 30 Europe Skin Cancer Market Share, By End-User, 2024 & 2033 (%)
Figure 31 Europe Skin Cancer Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Skin Cancer Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Skin Cancer Market Share, By Treatment, 2024 & 2033 (%)
Figure 35 Asia-Pacific Skin Cancer Market Share, By End-User, 2024 & 2033 (%)
Figure 36 Asia-Pacific Skin Cancer Market Share, By Country, 2024 & 2033 (%)
Figure 37 South America Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 38 South America Skin Cancer Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 39 South America Skin Cancer Market Share, By Treatment, 2024 & 2033 (%)
Figure 40 South America Skin Cancer Market Share, By End-User, 2024 & 2033 (%)
Figure 41 South America Skin Cancer Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Skin Cancer Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Skin Cancer Market Share, By Cancer Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Skin Cancer Market Share, By Treatment, 2024 & 2033 (%)
Figure 45 Middle East and Africa Skin Cancer Market Share, By End-User, 2024 & 2033 (%)
Figure 46 Merck & Co., Inc.: Financials
Figure 47 Amgen, Inc.: Financials
Figure 48 Pfizer Inc.: Financials
Figure 49 Genentech USA, Inc.: Financials
Figure 50 Regeneron Pharmaceuticals, Inc.: Financials
Figure 51 Bristol-Myers Squibb Company: Financials
Figure 52 Sun Pharmaceutical Industries, Inc.: Financials
Figure 53 Immunocore Ltd.: Financials
Figure 54 IOVANCE Biotherapeutics, Inc.: Financials
Figure 55 Incyte: Financials